1 / 18

XVIII International AIDS Conference, Vienna, 2010

Track A Report Guido Poli Vita-Salute San Raffaele University & Scientific Institute, Milano, Italy. XVIII International AIDS Conference, Vienna, 2010 . Track A - Rapporteur talk. HIV life cycle: road map for anti-HIV drug discovery

jonny
Télécharger la présentation

XVIII International AIDS Conference, Vienna, 2010

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Track A ReportGuido PoliVita-Salute San Raffaele University & Scientific Institute, Milano, Italy XVIII International AIDS Conference, Vienna, 2010

  2. Track A - Rapporteur talk • HIV life cycle: road map for anti-HIV drug discovery • New findings in LTNP & Elite Controllers: keys for vaccine development • The hardest target: HIV persistence in latently infected cells and reservoirs • Concluding remarks

  3. Track A - Rapporteur talk • HIV life cycle: road map for anti-HIV drug discovery • New findings in LTNP & Elite Controllers: keys for vaccine development • The hardest target: HIV persistence in latently infected cells and reservoirs • Concluding remarks

  4. The HIV Life Cycle... Courtesy of Anthony S. Fauci, Bethesda, USA

  5. …Road Map for Anti-HIV Drug Discovery Courtesy of Anthony S. Fauci, Bethesda, USA

  6. …Road Map for Anti-HIV Drug Discovery TBR-652 (D.E. Martin) LEDGINs (F. Christ)

  7. Track A - Rapporteur talk • HIV life cycle: road map for anti-HIV drug discovery • New findings in LTNP & Elite Controllers: keys for vaccine development • The hardest target: HIV persistence in latently infected cells and reservoirs • Concluding remarks

  8. Natural Control of HIV Infection • Long-Term Non Progressors (LTNP) • >7-10 years of infection • No therapy • No symptoms • Stable CD4+ T-cell counts > 500/mm3 • 1-5 % of all infected individuals • Elite & Viremic Controllers* • plasma viremia < 50 copies/ml for >1 year • No therapy • *As above, but with viremia <2,000 copies/ml • <1% of all infected individuals Adapted from Sara Rowland-Jones, Oxford, U.K.

  9. TCM Protective HLA-B Alleles Limit HIV Infection of CD4+ (central) Memory Cells TTM TEM TN % infected CD4 T cells subsets Benjamin Descours, Paris, France

  10. p=0.0159 p=0.0079 p21 b-actin HIV neg EC progressors 2 4 2 4 1 1 3 3 5 5 2 4 1 3 n=5 n=5 n=4 HIV neg EC progressors CD4+ T cells from Elite Controllers Resist HIV-1 Infection by Upregulation of p21 • Inhibitor of Cyclin-dependent kinases • Contributes to resistance of monocyte/macrophages and hematopoietic stem cells to HIV-1 infection • Interferes with HIV-1 both pre- and post-proviral DNA integration Mathias Lichterfeld, Boston, USA

  11. MicroRNA Expression Pattern May Discriminate HIV Exposure from Infection • miRNAs are short RNA molecules that bind to complementary sequences in the 3' UTR of target mRNAs, usually resulting in gene silencing • The human genome may encode over 1,000 miRNAs,targeting about 60% of mammalian genes • Aberrant expression of miRNAs has been implicated in numerous diseases; miRNA-based therapies are under investigation.

  12. MicroRNA Expression Pattern May Discriminate HIV Exposure from Infection • MEU (multiply Exposed Uninfected) show a prevalent downregulation of miRNAs • LTNP show a prevalent upregulation of miRNAs Claudio Casoli, Milano, Italy MEU Naïve LTNP

  13. Track A - Rapporteur talk • HIV life cycle: road map for anti-HIV drug discovery • New findings in LTNP & Elite Controllers: keys for vaccine development • The hardest target: HIV persistence in latently infected cells and reservoirs • Concluding remarks

  14. HAART Gene therapy Inhibit HIV replication shRNA (tat/rev, TAR) Reduce CCR5 Potential Approaches Towards “The Cure” (i.e., HIV Eradication) Activated CD4+ T-cell Resting CD4+ T-cell Sharon R. Lewin, Melbourne, Australia

  15. Transactivator CDK9 CycT1 Deciphering the Transcriptional Complex Recruited by HIV-1 Tat… Drugs:TSA, Prostratin,… P-TEFb PS-2 CTD Tar-RNA CTD PS-5 PS-5 Pol-II Pol-II NTEFs NTEFs Latent provirus / stalled LTR Activated provirus MonsefBenkirane, Montpellier, France

  16. …An Important Lead to New HIV Drug Discovery PAF1 CDC73 Processive elongation Activating signals CDK9 CDK9 CycT1 CycT1 Latency Core P-TEFb Virus Production Active/elongating P-TEFb Structure of the Tat associated P-TEFbcomplex may provide opportunities to design inhibitory peptides or reactivate latent HIV-1 and purging the reservoirs AFF1 AFF4 EAF1 ELL ENL AF9 MonsefBenkirane, Montpellier, France)

  17. Track A - Rapporteur talk • HIV life cycle: road map for anti-HIV drug discovery • New findings in LTNP & Elite Controllers: keys for vaccine development • The hardest target: HIV persistence in latently infected cells and reservoirs • Concluding remarks

  18. The Track A Rapporteur’s Team! RienkJeeninga (The Netherlands) TakafiraMduluza (Botszwana) LavinaGaru (India) Patricia Monteiro (Canada)

More Related